Abstract
Alzheimer disease (AD) is the most common cause of dementia in adults. Aberrant hyperphosphorylation of microtubule associated protein Tau and neurofilament-M/H is one of the pathological hallmarks of AD. Most of the therapeutic strategies for treating AD are based on the inhibition of protein kinases such as glycogen synthase kinase-3β, cyclin- dependent kinase 5, and other Tau kinases. Here, we focus on protein phosphatase 2A (PP2A) as a key player in AD. PP2A expression and activity are downregulated in AD brain, contributing to the aberrant phosphorylation of Tau and NF proteins in AD. Recent data published from our lab as well as others on PP2A deregulation in AD is reviewed. The role of peptidyl prolyl isomerase Pin1 in regulation of PP2A mediated neurodegeneration is further analyzed. Development of drugs for AD could be based on restoration of PP2A activity or targeting Pin1.
Keywords: Alzheimer's disease, tau, Neurofilaments, protein dephosphorylation, protein kinases, phosphatases, protein phosphatase 2A, Pin1, NFT, progressive dementia, hyperphosphorylation, Tau mutation, cerebral infusion, FTDP17
Current Alzheimer Research
Title: Role of Protein Phosphatase 2A in Alzheimers Disease
Volume: 8 Issue: 6
Author(s): P. Rudrabhatla and H. C. Pant
Affiliation:
Keywords: Alzheimer's disease, tau, Neurofilaments, protein dephosphorylation, protein kinases, phosphatases, protein phosphatase 2A, Pin1, NFT, progressive dementia, hyperphosphorylation, Tau mutation, cerebral infusion, FTDP17
Abstract: Alzheimer disease (AD) is the most common cause of dementia in adults. Aberrant hyperphosphorylation of microtubule associated protein Tau and neurofilament-M/H is one of the pathological hallmarks of AD. Most of the therapeutic strategies for treating AD are based on the inhibition of protein kinases such as glycogen synthase kinase-3β, cyclin- dependent kinase 5, and other Tau kinases. Here, we focus on protein phosphatase 2A (PP2A) as a key player in AD. PP2A expression and activity are downregulated in AD brain, contributing to the aberrant phosphorylation of Tau and NF proteins in AD. Recent data published from our lab as well as others on PP2A deregulation in AD is reviewed. The role of peptidyl prolyl isomerase Pin1 in regulation of PP2A mediated neurodegeneration is further analyzed. Development of drugs for AD could be based on restoration of PP2A activity or targeting Pin1.
Export Options
About this article
Cite this article as:
Rudrabhatla P. and C. Pant H., Role of Protein Phosphatase 2A in Alzheimers Disease, Current Alzheimer Research 2011; 8 (6) . https://dx.doi.org/10.2174/156720511796717168
DOI https://dx.doi.org/10.2174/156720511796717168 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antioxidant Nanoparticles for Control of Infectious Disease
Infectious Disorders - Drug Targets Editorial (Thematic Issue: The Monocyte/Macrophage in the Pathogenesis of AIDS: The Next Frontier for Therapeutic Intervention in the CNS and Beyond: Part I)
Current HIV Research Amaranth: A Pseudo-Cereal with Nutraceutical Properties
Current Nutrition & Food Science Cell Life Versus Cell Longevity: The Mysteries Surrounding the NAD+ Precursor Nicotinamide
Current Medicinal Chemistry The Long Non-Coding RNAs in Neurodegenerative Diseases: Novel Mechanisms of Pathogenesis
Current Alzheimer Research Diet and Neurocognition: Review of Evidence and Methodological Considerations
Current Aging Science Advances in the Treatment of Neurodegenerative Disorders Employing Nanoparticles
Recent Patents on Drug Delivery & Formulation Tuberculostatic Drugs Targeting Infections of the Central Nervous System
Anti-Infective Agents Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases
Mini-Reviews in Medicinal Chemistry The Evolution of Schizophrenia: A Model for Selection by Infection, with a Focus on NAD
Current Pharmaceutical Design Anti-inflammatory strategies in stroke: a potential therapeutic target
Current Vascular Pharmacology The Differential Diagnostic Value of the Callosal Angle and Evans Index in Mild Cognitive Impairment and Alzheimer's Disease
Current Medical Imaging Retromer Dysfunction and Neurodegenerative Disease
Current Genomics Blood-Brain Barrier ABC-transporter P-glycoprotein in Alzheimer's Disease: Still a Suspect?
Current Pharmaceutical Design Increased Epileptiform EEG Activity and Decreased Seizure Threshold in Arctic APP Transgenic Mouse Model of Alzheimer’s Disease
Current Alzheimer Research A Therapeutic Connection between Dietary Phytochemicals and ATP Synthase
Current Medicinal Chemistry PDE-5 Inhibitors: Clinical Points
Current Drug Targets Future Targeted Disease Modifying Drugs for Alzheimer's Disease
Recent Patents on CNS Drug Discovery (Discontinued) Pre-CKD- Do we Need Another Hero?
Current Vascular Pharmacology Central Nervous System Depressants and Risk of Hospitalization due to Community-Acquired Pneumonia in very Old Patients
Current Drug Safety